Current development of mTOR inhibitors as anticancer agents
about
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapyDeregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimusUpdates of mTOR inhibitorsStronger is not always better: could a bodybuilding dietary supplement lead to ALS?The mTOR signalling pathway in human cancerRegulation of autophagy by cytoplasmic p53Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomasRapamycin and rapalogs for tuberous sclerosis complexThe pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsTargeting mTOR in Pancreatic Ductal AdenocarcinomaManagement of immunosuppressant agents following liver transplantation: Less is moreBiomarkers in triple negative breast cancer: A reviewTumour Angiogenesis and Angiogenic Inhibitors: A ReviewNew molecular targets in mantle cell lymphomaMammalian target of rapamycin inhibitor-associated stomatitisChloroquine and hydroxychloroquine for cancer therapyTargeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesDeregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targetsDifferentiating mTOR inhibitors in renal cell carcinomaPI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsMolecular therapy of colorectal cancer: progress and future directionsTargeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastomaRapamycin Promotes Mouse 4T1 Tumor Metastasis that Can Be Reversed by a Dendritic Cell-Based VaccineA systematic interaction map of validated kinase inhibitors with Ser/Thr kinasesThe therapeutic potential of targeting the PI3K pathway in pediatric brain tumorsPim kinase inhibitors: a survey of the patent literatureInflammatory conditions induce IRES-dependent translation of cyp24a1Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathwayPI3K/PTEN signaling in angiogenesis and tumorigenesisA systematic analysis of a mi-RNA inter-pathway regulatory motifRtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysemaAntitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastomaProton-shuttling lichen compound usnic acid affects mitochondrial and lysosomal function in cancer cellsMetformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cellsU12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathwaysc-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformationTargeting cancer with small molecule kinase inhibitorsTargeting the phosphoinositide 3-kinase pathway in cancerInhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
P2860
Q21145847-C0778960-C698-4A27-BCEE-E0093E7D574FQ21198871-9AC153A1-1F72-4D7A-9AD0-083E4B41E209Q24600932-74B48AD5-4D42-40BA-9ACF-81D641BBE308Q24607170-16621EA4-4465-49B6-94A8-7B9C905812F2Q24607879-83A0830E-DADC-4116-A35C-BE8E942B6AD0Q24627306-01A1370A-D94B-49D2-BDAC-2D26B10BB39BQ24651258-B6D702DC-38FE-46CE-8210-463229CE2E70Q24658269-69FE2177-FACB-48A4-8828-ABFF163FE551Q26471128-17671EA2-B554-4A61-A45C-2DA1A2C5C2AFQ26740374-9D6333C3-A518-4A64-B6D8-0DE92722CA92Q26747291-B32BF489-35B7-4C4B-B8F2-E8FD6A86EF3CQ26770033-C6989B9C-3558-466C-9667-E5D713C4798DQ26775094-77DF758D-47D3-434E-9F0A-881F25D718C0Q26798822-EF9DB429-BC92-4C8F-903E-C52117DF5E56Q26821766-6711EF7E-3E55-4651-AFDE-FD58118B5AC3Q26825301-47FE9A24-F4C7-42A4-964B-B639AA5D6765Q26827797-301A1BEC-A493-4AEE-88D7-C75945DC480AQ26829652-ADCFF244-5C3C-452C-AC1B-81F710DCE738Q26829873-6C68E0E5-AF3A-4295-95A7-13A26830F730Q26860172-26A1A3E1-7F61-4479-B5E6-B7FBD514755AQ26862544-23A66485-7770-42C6-82C5-9402B06BC365Q27005764-F47195FB-335A-4531-B38B-BCFD72488246Q27022941-1ACBED30-7661-42A6-8D82-A758AA772E48Q27317214-C08EAB27-F932-4639-8C3B-B15903A186C7Q27649303-FE7C1316-27A5-412F-A5EA-6FC96A4F9758Q28070264-5BC0FB2B-29D2-4F2B-9C11-2F4551616DFFQ28271318-13BF4532-BBBE-48C5-A31E-B8EEB025AB70Q28305723-82EA38F5-4735-4B59-A791-8E24A8555B74Q28382812-7249D31D-E9D7-4C0C-B3EB-017D527DD711Q28383083-A474ACDB-A96D-4B8B-AF6D-AE2337C5D55EQ28393475-34687B2E-6722-4477-8067-2F43A23E1305Q28397712-739699E7-889E-4C7F-9D37-229420A80FD0Q28472048-15A14430-D428-4835-82D5-07665D062F86Q28485469-9DDFDB30-E953-4CED-8389-C6ACB3CA1D15Q28539104-EBBC654E-8E55-4BC7-8866-72C07F14F444Q28542555-E5616AD6-0DA3-4E08-84AF-E6A924DCAB91Q28573044-E0B874D0-516A-462E-AB01-AEB5F7627EC0Q29547395-3510339E-1083-41F3-8A1E-BFF2829DF9A4Q29615809-2528571D-EE55-455F-8D2E-D072E01C8770Q29618030-F2C9D2CC-6657-45E8-876D-4F7C8E2CBCF6
P2860
Current development of mTOR inhibitors as anticancer agents
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Current development of mTOR inhibitors as anticancer agents
@ast
Current development of mTOR inhibitors as anticancer agents
@en
Current development of mTOR inhibitors as anticancer agents
@nl
type
label
Current development of mTOR inhibitors as anticancer agents
@ast
Current development of mTOR inhibitors as anticancer agents
@en
Current development of mTOR inhibitors as anticancer agents
@nl
prefLabel
Current development of mTOR inhibitors as anticancer agents
@ast
Current development of mTOR inhibitors as anticancer agents
@en
Current development of mTOR inhibitors as anticancer agents
@nl
P2860
P3181
P356
P1476
Current development of mTOR inhibitors as anticancer agents
@en
P2093
Eric Raymond
P2860
P2888
P304
P3181
P356
10.1038/NRD2062
P407
P577
2006-08-01T00:00:00Z